An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Graphite Bio Announces Participation in Jefferies Healthcare Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Graphite Bio, Inc. (NASDAQ: GRPH), a clinical-stage gene editing company, announced that its management will present at the Jefferies Healthcare Conference on June 8, 2022, at 4 p.m. ET. The presentation will be accessible via a live webcast on Graphite Bio's website. The company focuses on next-generation precision gene repair technology, aiming to treat serious diseases through its UltraHDR™ platform, which allows for precise genetic modifications. Co-founded by experts in gene therapy, Graphite Bio strives to revolutionize treatments by accurately modifying genes.
Positive
Management will present at Jefferies Healthcare Conference, increasing visibility.
Focus on next-generation gene editing could lead to innovative therapies.
UltraHDR™ platform aims to correct genetic mutations, which is a significant advancement.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.
The presentation will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform is designed to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
What is the significance of Graphite Bio's presentation at the Jefferies Healthcare Conference on June 8, 2022?
The presentation will increase the company's visibility among investors and industry peers, showcasing its innovative gene editing technologies.
How does Graphite Bio's UltraHDR™ platform work?
The UltraHDR™ platform allows for precise corrections of genetic mutations, replacement of disease-causing genes, and insertion of new genes into safe genomic locations.
What is the ticker symbol for Graphite Bio?
Graphite Bio is listed on NASDAQ under the ticker symbol GRPH.
Who co-founded Graphite Bio?
Graphite Bio was co-founded by Maria Grazia Roncarolo and Matthew Porteus, both renowned in gene editing and therapy.
